Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1996 2
1997 4
1998 2
1999 1
2000 1
2002 3
2003 2
2004 8
2005 3
2006 5
2007 4
2008 12
2009 10
2010 10
2011 12
2012 19
2013 12
2014 11
2015 20
2016 24
2017 21
2018 20
2019 30
2020 25
2021 30
2022 30
2023 24
2024 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Results by year

Filters applied: . Clear all
Page 1
TIL Therapy: Facts and Hopes.
Monberg TJ, Borch TH, Svane IM, Donia M. Monberg TJ, et al. Among authors: svane im. Clin Cancer Res. 2023 Sep 1;29(17):3275-3283. doi: 10.1158/1078-0432.CCR-22-2428. Clin Cancer Res. 2023. PMID: 37058256 Review.
In vivo dendritic cell reprogramming for cancer immunotherapy.
Ascic E, Åkerström F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, Catena X, Rotankova N, Veser C, Rudnik M, Ballocci T, Schärer T, Huang X, de Rosa Torres M, Renaud E, Velasco Santiago M, Met Ö, Askmyr D, Lindstedt M, Greiff L, Ligeon LA, Agarkova I, Svane IM, Pires CF, Rosa FF, Pereira CF. Ascic E, et al. Among authors: svane im. Science. 2024 Oct 18;386(6719):eadn9083. doi: 10.1126/science.adn9083. Epub 2024 Oct 18. Science. 2024. PMID: 39236156 Free PMC article.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Restoring tumor immunogenicity with dendritic cell reprogramming.
Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met Ö, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silvério-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF. Zimmermannova O, et al. Among authors: svane im. Sci Immunol. 2023 Jul 14;8(85):eadd4817. doi: 10.1126/sciimmunol.add4817. Epub 2023 Jul 7. Sci Immunol. 2023. PMID: 37418548 Free PMC article.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: svane im. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Lövgren K, Warren S, Jirström K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, Jönsson G. Cabrita R, et al. Among authors: svane im. Nature. 2020 Jan;577(7791):561-565. doi: 10.1038/s41586-019-1914-8. Epub 2020 Jan 15. Nature. 2020. PMID: 31942071
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.
Dolton G, Rius C, Wall A, Szomolay B, Bianchi V, Galloway SAE, Hasan MS, Morin T, Caillaud ME, Thomas HL, Theaker S, Tan LR, Fuller A, Topley K, Legut M, Attaf M, Hopkins JR, Behiry E, Zabkiewicz J, Alvares C, Lloyd A, Rogers A, Henley P, Fegan C, Ottmann O, Man S, Crowther MD, Donia M, Svane IM, Cole DK, Brown PE, Rizkallah P, Sewell AK. Dolton G, et al. Among authors: svane im. Cell. 2023 Aug 3;186(16):3333-3349.e27. doi: 10.1016/j.cell.2023.06.020. Epub 2023 Jul 24. Cell. 2023. PMID: 37490916 Free article.
Principles of adoptive T cell therapy in cancer.
Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Met Ö, et al. Among authors: svane im. Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Semin Immunopathol. 2019. PMID: 30187086 Review.
329 results